Showing 1241-1250 of 3001 results for "".
- Research Presented at ANA 2024 Reveals Association Between Paramagnetic Rim Lesions and Disability/Disease Progression in People with MShttps://practicalneurology.com/news/research-presented-at-ana-2024-reveals-association-between-paramagnetic-rim-lesions-and-disabilitydisease-progression-in-people-with-ms/2470577/For people with multiple sclerosis (MS), a higher number of persisting paramagnetic rim lesions (PRLs) was associated with increased odds of progression independent of relapse activity (PIRA) and confirmed disability progression (CDP), according to data presented at the 2024 annual meeting of the
- Access and Cost of Neurologic Health Care May Provide a Link Between MS and Latitudehttps://practicalneurology.com/news/access-and-cost-of-neurologic-health-care-may-provide-a-link-between-ms-and-latitude/2470007/According to new research published in Neurology, the correlation between lower incidence of multiple sclerosis (MS) diagnosis and distance from the equator may be due to issues of access to care rather than biologic mechanisms of disease. The study results suggest undere
- FDA Approves Ofatumumab—First and Only Self-administered B-cell Therapy for Relapsing MShttps://practicalneurology.com/news/fda-approves-ofatumumab-first-and-only-self-administered-b-cell-therapy-for-relapsing-ms/2469358/The Food and Drug Administration (FDA) has approved ofatumumab (Kesimpta; Novartis) as an subcutaneous autoinjection for treatment of relapsing forms of multiple sclerosis (RS), including clinically isolated syndrome (CIS), relapsing-remitting disease (RRMS), and active secondary progressive MS (
- Tolebrutinib vs Teriflunomide Treatment for Individuals with Relapsing MShttps://practicalneurology.com/news/study-compares-tolebrutinib-vs-teriflunomide-as-treatment-for-individuals-with-relapsing-ms/2473966/Analysis of results from two clinical trials presented at the American Academy of Neurology (AAN) 2025 Annual Meeting revealed no significant difference in the adjusted annualized relapse rate (ARR) in individuals with relapsing multiple sclerosis (RMS) treated with either tolebrutinib (Sanofi; B
- Antidepressants Safe in Those Taking Ozanimod for Relapsing MShttps://practicalneurology.com/news/antidepressants-safe-in-those-taking-ozanimod-for-relapsing-ms/2470123/Data presented at the Americas Committee for Treatment & Research in Multiple Sclerosis (ACTRIMS) Forum 2023 suggest that concurrent administration of ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) with selectiv
- Standard Health Outcomes Recommended for Relapsing-Remitting MShttps://practicalneurology.com/news/standard-health-outcomes-recommended-for-relapsing-remitting-ms/2470122/A multidisciplinary scientific committee reported on their initiative to define a set of standard health outcomes for relapsing-remitting multiple sclerosis (R
- Ozanimod Comparable to Diroximel Fumarate for Relapsing-Remitting MShttps://practicalneurology.com/news/ozanimod-comparable-to-diroximel-fumarate-for-relapsing-remitting-ms/2470121/According to results from a matching-adjusted indirect comparison study, ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) had
- Biosimilar Found Equivalent to Natalizumab for Relapsing-Remitting MShttps://practicalneurology.com/news/biosimilar-found-equivalent-to-natalizumab-for-relapsing-remitting-ms/2470108/
- Masitinib Reduced Disability Progression in People With Progressive MShttps://practicalneurology.com/news/masitinib-reduced-disability-progression-in-people-with-progressive-ms/2469840/As published in Neurology Neuroimmunology & Neuroinflammation, results from a phase 3 trial (NCT01433497) of masitinib (AB Science; Paris, Franc
- Positive Phase 2 Results for Evobrutinib Treatment of MS and Initiation of Phase 3 Trialshttps://practicalneurology.com/news/positive-phase-2-results-for-evobrutinib-treatment-of-ms-and-initiation-of-phase-3-trials/2469014/At the European Committee on Research and Treatment in Multiple Sclerosis (ECTRIMS) Congress in Stockholm, Sweden September 11-13, 2019, data from a phase 2 trial (NCT02975349) of evobrutinib (EMD Serono, Rockland, MD) for treatment of